Aimmune Therapeutics (AIMT) Receives New Coverage from Analysts at Cantor Fitzgerald
Cantor Fitzgerald started coverage on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research note issued to investors on Tuesday morning. The brokerage issued an overweight rating on the biotechnology company’s stock.
A number of other brokerages have also recently issued reports on AIMT. Roth Capital initiated coverage on shares of Aimmune Therapeutics in a research report on Monday, November 20th. They set a buy rating and a $60.00 price target for the company. Zacks Investment Research raised shares of Aimmune Therapeutics from a sell rating to a hold rating in a research report on Monday, October 16th. Wedbush reissued an ourperform rating and set a $42.00 price target on shares of Aimmune Therapeutics in a research report on Monday, August 14th. Piper Jaffray Companies lifted their price target on shares of Aimmune Therapeutics from $38.00 to $60.00 and gave the company an overweight rating in a research report on Tuesday, December 5th. Finally, BidaskClub cut shares of Aimmune Therapeutics from a buy rating to a hold rating in a research report on Saturday. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $53.80.
Shares of Aimmune Therapeutics (NASDAQ:AIMT) traded down $0.56 during midday trading on Tuesday, reaching $33.60. 353,400 shares of the company were exchanged, compared to its average volume of 357,500. Aimmune Therapeutics has a one year low of $15.97 and a one year high of $38.86.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.09. equities analysts anticipate that Aimmune Therapeutics will post -2.52 earnings per share for the current year.
In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 1,906 shares of Aimmune Therapeutics stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $38.66, for a total value of $73,685.96. Following the completion of the transaction, the insider now directly owns 1,906 shares of the company’s stock, valued at $73,685.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Stephen George Dilly sold 100,000 shares of Aimmune Therapeutics stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $25.01, for a total transaction of $2,501,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 274,986 shares of company stock valued at $7,533,100. 17.59% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently modified their holdings of AIMT. SG Americas Securities LLC raised its holdings in Aimmune Therapeutics by 10.1% in the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after buying an additional 499 shares during the last quarter. Legal & General Group Plc raised its holdings in Aimmune Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after buying an additional 1,634 shares during the last quarter. Voya Investment Management LLC raised its holdings in Aimmune Therapeutics by 31.2% in the second quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock worth $324,000 after buying an additional 3,757 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Aimmune Therapeutics in the second quarter worth about $333,000. Finally, Citadel Advisors LLC purchased a new position in Aimmune Therapeutics in the second quarter worth about $360,000. 73.34% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/13/aimmune-therapeutics-aimt-receives-new-coverage-from-analysts-at-cantor-fitzgerald.html.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.